-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
With great success in the treatment of various solid tumors and lymphomas , immune checkpoint inhibitors (CPIs) are currently being studied as an immunotherapy option for patients with acute myeloid leukemia (AML)
.
The incidence and extent of infection in patients with acute myeloid leukemia (AML) treated with a combination of immune checkpoint inhibitors (CPI) and hypomethylation agents (HMA) are not known
With great success in the treatment of various solid tumors and lymphomas , immune checkpoint inhibitors (CPIs) are currently being studied as an immunotherapy option for patients with acute myeloid leukemia (AML)
Nivolumab is a PD-1 checkpoint inhibitor that has been approved in many solid tumors and lymphomas
Table 1: Univariate analysis of the characteristics of the patients and the treatments they received
Table 2: Infections diagnosed during the study
Table 2: Diagnosis of infections diagnosed during the study
During the study period, 64 (85%) patients developed infections, and bacterial infections are by far the most common type of infection
.
Comparison of risk factors and characteristics between 75 CPI patients who developed infections and patients who were not found to use corticosteroids (odds ratio [OR], 28; 95% confidence interval [CI], 1.
6-490; P = .
02 ) And lymphopenia (OR, 4; 95% CI, 1-15.
5; P = .
04) were significantly associated with infection
In conclusion, compared with patients who did not receive ipi-based therapy, patients with relapsed/refractory AML were more likely to develop severe infections when treated with corticosteroids in an irAE setting
Original source:
Original source:Spallone A,Alotaibi AS,Jiang Y,et al.
Infectious Complications Among Patients With AML Treated With Immune Checkpoint Inhibitors.
[J].
Clin Lymphoma Myeloma Leuk,1970,:.
Spallone A,Alotaibi AS,Jiang Y,et al.
Infectious Complications Among Patients With AML Treated With Immune Checkpoint Inhibitors.
[J].
Clin Lymphoma Myeloma Leuk,1970,:.
Leave a message here
